ULTIMATE ACHIEVEMENT
Can buildings make a difference for the people who live and work in them? The power of design is an article of faith for architects, but the ultimate verification comes from the evidence presented by the users—individuals who actually inhabit their designs. Here’s testimony from one who worked at at Paul Rudolph’s Burroughs Wellcome building:
I spent 32 years with [Burroughs Wellcome]. . . .and helped work on the layout of the labs to fit the 22.5 degree sloping walls of bright orange and blue. At that time, if any space was conceived to bring out the creative, inspirational, thoughts—this was it, in my opinion. I loved working there. We invented and developed more pharmaceutical products in those years. . . .We were “family” but more to the point we were colleagues who were allowed to trust the expertise of each other.
Even more convincing evidence of the positive environment of the building is the work which emerged from Burroughs Wellcome: the scientific research, and the products which were the practical application of that research. When that research saves, ultimately, many millions of lives, there could be no finer acknowledgement of great human and scientific accomplishment—but when the creators of that work is then recognized by the world’s most distinguished judges, one has risen to a level few ever achieve.
That is what happened with the work of Gertrude Elion and George Hitchings. It was for their work over decades (and particularly the work done while they were at the Burroughs Wellcome building in North Carolina’s Research Triangle Park) that they became Nobel Prize laureates in Medicine in 1988.
THE NOBEL PRIZE
Here are excerpts from the official announcement of Elion’s and Hitchings’ prize:
The Nobel Assembly at the Karolinska Institute has today decided to award the Nobel Prize in Physiology or Medicine for 1988 jointly to Sir James W. Black, Gertrude B. Elion and George H. Hitchings.
The discoveries awarded with this year’s Nobel Prize in Physiology or Medicine concern important principles in drug treatment, principles that have resulted in the development of a series of new drugs.. . .
The discoveries awarded with this year’s Nobel Prize in Physiology or Medicine concern the development of new drugs which have become essential in the treatment of a number of different disorders, mainly myocardial ischemia (angina pectoris), hypertension, gastroduodenal ulcer, leukemia, gout and infectious diseases. However, the research work carried out by Black, Elion and Hitchings has had a more fundamental significance. While drug development had earlier mainly been built on chemical modification of natural products they introduced a more rational approach based on the understanding of basic biochemical and physiological processes.
. . . .An even more recent application of these ideas is the development of azidothymidine (AZT) which was described in 1985 by other scientists from the same institute, and which is the hitherto best documented drug in the treatment of AIDS. It can be added that trimethoprim-sulfa is used in the treatment of Pneumocystis carinii, a relatively common complication to AIDS.
The Burroughs Wellcome building was renamed the Elion-Hitchings Building in 1988, honoring Gertrude Elion and George Hitchings. It’s worth speaking of their careers and research—including the era when they were working at the Burroughs Wellcome building in Research Triangle Park.
GERTRUDE ELION
(1918-1999) From 1967 to 1983, Elion was the Head of the Department of Experimental Therapy for Burroughs Wellcome. She officially retired in 1983—but even after her retirement from Burroughs Wellcome, she continued almost full-time work at the lab. She played a significant role in the development of AZT, one of the first drugs used to treat HIV and AIDS.
Rather than relying on trial-and-error, Elion and Hitchings discovered new drugs using rational drug design, which used the differences in biochemistry and metabolism between normal human cells and pathogens (disease-causing agents such as cancer cells, protozoa, bacteria, and viruses) to design drugs that could kill or inhibit the reproduction of particular pathogens without harming human cells. The drugs they developed are used to treat a variety of maladies, such as leukemia, malaria, lupus, hepatitis, arthritis, gout, and organ transplant rejection.
Elion was Adjunct Professor of Pharmacology and of Experimental Medicine from 1971 to 1983, and Research Professor at Duke University from 1983 to 1999. She was elected a member of the National Academy of Sciences in 1990, a member of the Institute of Medicine in 1991, and a Fellow of the American Academy of Arts and Sciences also in 1991.
gEORGE HITCHINGS
(1905-1998) In 1942, Hitchings went to work for Wellcome Research Laboratories at in their Tuckahoe laboratory (their US research center, before it was moved to North Carolina). There, he began working with Gertrude Elion in 1944. Drugs Hitchings' team worked on included 2,6-diaminopurine (a compound to treat leukemia) and p-chlorophenoxy-2,4-diaminopyrimidine (a folic acid antagonist). According to his Nobel Prize autobiography,
The line of inquiry we had begun in the 1940s [also] yielded new drug therapies for malaria (pyrimethamine), leukemia (6-mercaptopurine and thioguanine), gout (allopurinol), organ transplantation (azathioprine) and bacterial infections (co-trimoxazole (trimethoprim A)). The new knowledge contributed by our studies pointed the way for investigations that led to major antiviral drugs. . [including for] AIDS (zidovudine).
In 1967 Hitchings became Vice President in Charge of Research of Burroughs-Wellcome. He became Scientist Emeritus in 1976. He also served as Adjunct Professor of Pharmacology and of Experimental Medicine from 1970 to 1985 at Duke University.
YOU CAN HELP SAVE BURROUGHS WELLCOME !
The Burroughs Wellcome building is threated with imminent demolition.
It’s loss would be a disaster—a titanic waste of our nation’s cultural heritage.
When a great building is destroyed, there are no second chances.
NOW— THERE ARE TWO THINGS YOU CAN DO:
Sign the petition to save Burroughs Wellcome. You can sign it here.
We’ll send you bulletins about the latest developments. To get them, please join our foundation’s mailing list: you’ll get all the updates, (as well as other Rudolphian news.)—you can sign up at the bottom of this page.